A Phase II Trial of Tipifarnib (R115777, Zarnestra™) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Hormone Receptor-Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2018
At a glance
- Drugs Fulvestrant (Primary) ; Tipifarnib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jul 2007 Status change from suspended to in progress.
- 05 Aug 2005 New trial record.